Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) EBIT Margin (2020 - 2023)

Historic EBIT Margin for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to 228.43%.

  • Candel Therapeutics' EBIT Margin rose 259038300.0% to 228.43% in Q4 2023 from the same period last year, while for Dec 2023 it was 1479.42%, marking a year-over-year increase of 265213800.0%. This contributed to the annual value of 1596.7% for FY2024, which is 1172800.0% down from last year.
  • According to the latest figures from Q4 2023, Candel Therapeutics' EBIT Margin is 228.43%, which was up 259038300.0% from 1324.51% recorded in Q3 2023.
  • Candel Therapeutics' EBIT Margin's 5-year high stood at 1581.77% during Q1 2023, with a 5-year trough of 28987.1% in Q1 2022.
  • Over the past 4 years, Candel Therapeutics' median EBIT Margin value was 17100.0% (recorded in 2021), while the average stood at 15193.5%.
  • Its EBIT Margin has fluctuated over the past 5 years, first plummeted by -170322600bps in 2021, then soared by 305688700bps in 2023.
  • Quarter analysis of 4 years shows Candel Therapeutics' EBIT Margin stood at 19758.06% in 2020, then fell by -26bps to 24967.74% in 2021, then dropped by -5bps to 26132.26% in 2022, then surged by 99bps to 228.43% in 2023.
  • Its EBIT Margin stands at 228.43% for Q4 2023, versus 1324.51% for Q3 2023 and 1487.42% for Q2 2023.